Hanspeter Spek - Celyad SA Non-Executive Director

CYAD Stock  EUR 0.73  0.09  14.06%   

Director

Mr. Hanspeter Spek was appointed as a NonExecutive Member of the Board of Directors of Cardio3 Biosciences SA as of May 5, 2014. He started his career at Pfizer where, over more than 10 years and after a training in commercial general management, he held positions of increasing responsibility. He then joined Sanofi as Marketing Director and rose through the organization to become the Executive Vice President International in 2000. When Sanofi and Aventis merged in 2004, he took on the responsibility of Executive Vice President Operations. In 2009, he was nominated President Global Operations. He retired from Sanofi in mid2013. He has since joined Advent as a Senior Advisor for Healthcare. He continues to serve on the Board of Sanofi, Germany, as Chairman. since 2014.
Age 66
Tenure 10 years
Phone(32) 10 394 141
Webwww.celyad.com

Celyad SA Management Efficiency

The company has return on total asset (ROA) of (0.2933) % which means that it has lost $0.2933 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9264) %, meaning that it generated substantial loss on money invested by shareholders. Celyad SA's management efficiency ratios could be used to measure how well Celyad SA manages its routine affairs as well as how well it operates its assets and liabilities.
Celyad SA has accumulated 3.4 M in total debt with debt to equity ratio (D/E) of 0.13, which may suggest the company is not taking enough advantage from borrowing. Celyad SA has a current ratio of 1.39, which is within standard range for the sector. Debt can assist Celyad SA until it has trouble settling it off, either with new capital or with free cash flow. So, Celyad SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Celyad SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Celyad to invest in growth at high rates of return. When we think about Celyad SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Laura CioliSofina Socit Anonyme
56
Analjit SinghSofina Socit Anonyme
65
Gwill YorkSofina Socit Anonyme
N/A
Nicolas BoelSofina Socit Anonyme
57
Jacques EmsensSofina Socit Anonyme
55
Michele SioenSofina Socit Anonyme
53
Catherine SoubieSofina Socit Anonyme
53
Guy VerhofstadtSofina Socit Anonyme
N/A
Charlotte StroembergSofina Socit Anonyme
N/A
Laurent dArgenteuilSofina Socit Anonyme
N/A
Robert PeugeotSofina Socit Anonyme
69
Anja LangenbucherSofina Socit Anonyme
N/A
Etienne DavignonSofina Socit Anonyme
86
Tom BamelisAckermans Van Haaren
57
Michel TilmantSofina Socit Anonyme
66
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T cell-based therapies for the treatment of cancer. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. CELYAD ONCOLOGY operates under Biotechnology classification in Belgium and is traded on Brussels Stock Exchange. It employs 87 people. Celyad SA (CYAD) is traded on Euronext Brussels in Belgium and employs 95 people.

Management Performance

Celyad SA Leadership Team

Elected by the shareholders, the Celyad SA's board of directors comprises two types of representatives: Celyad SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celyad. The board's role is to monitor Celyad SA's management team and ensure that shareholders' interests are well served. Celyad SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celyad SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Anne Portzenheim, Communication Manager
Michel Lussier, Chairman of the Board, Co-Founder
David Georges, VP Admin
MD MBChB, Chief Officer
Gaetane Metz, Chief Operating Officer
Sara Zelkovic, Communications Director
Jaak Minten, Director Clinical Affairs, representing Fakkel SPRL
Carri Duncan, Vice President Corporate Development and Communications
Stephen Rubino, Chief Business Officer
Hannes Iserentant, Head Property
Roland GordonBeresford, Regulatory Affairs and IP Director
BME MBA, CFO, CoFounder
William Wijns, Non-Executive Director, permanent representative of the Cardiovascular Center Aalst CVBA
Hanspeter Spek, Non-Executive Director
Dominic Piscitelli, Independent Director
Richard Mountfield, Vice President of Global Regulatory Affairs
JeanMarc Heynderickx, Independent Director
Frdric Lehmann, VP Affairs
Peter Waele, Member of the Executive Management Committee, Vice President - Research & Development
Georges Rawadi, Vice President - Business Development
Serge Goblet, Non-Executive Director
Filippo Petti, Chief Executive Officer, Chief Financial Officer, Director
Louise Proulx, Independent Director
Maria Koehler, Independent Director
Philippe Nobels, Chief HR
Chris Buyse, Independent Director, permanent representative of Life Sciences Research Partners
An Phan, Head Legal
Rudy Dekeyser, Independent Director
Philippe Dechamps, Chief Legal Officer
Anne Moore, Vice President Corporate Strategy
Marina UdierBlagovic, Director
Seron Aymeric, Program Manager
Margo Roberts, Director

Celyad Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celyad SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Celyad SA

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celyad SA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celyad SA will appreciate offsetting losses from the drop in the long position's value.

Moving against Celyad Stock

  0.82COMB Compagnie du BoisPairCorr
  0.8BNB Banque nationalePairCorr
  0.79COFB Cofinimmo SAPairCorr
  0.71VGP VGP NVPairCorr
  0.6SOF Sofina Socit AnonymePairCorr
The ability to find closely correlated positions to Celyad SA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celyad SA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celyad SA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celyad SA to buy it.
The correlation of Celyad SA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celyad SA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celyad SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celyad SA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Celyad Stock Analysis

When running Celyad SA's price analysis, check to measure Celyad SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celyad SA is operating at the current time. Most of Celyad SA's value examination focuses on studying past and present price action to predict the probability of Celyad SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celyad SA's price. Additionally, you may evaluate how the addition of Celyad SA to your portfolios can decrease your overall portfolio volatility.